ITERIUM - Clinical benefits from an innovative antihypertensive treatment;ITERIUM - Klinischer nutzen einer neuartigen antihypertensiven behandlung

Journal fur Kardiologie

Volumn 10, Issue SUPPL. D, 2003, Pages 8-13

  Kourilsky, Olivier ^a  

^a Hopital Louise Michel   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; IMIDAZOLINE RECEPTOR; METHYLDOPA; NIFEDIPINE; PLACEBO; RILMENIDINE;

ADRENERGIC SYSTEM; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIURETIC THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSLIPIDEMIA; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MICROALBUMINURIA; REVIEW; RISK FACTOR; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0038071664     PISSN: 10240098     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Bricca G, Zhang J, Greney H, Dontenwill M, Stutzmann J, Belcourt A, Bousquet P. Human brain imidazoline receptors: further characterization with (3H)clonidine. Eur J Pharmacol Mol Pharmacol 1994; 266: 25-33.
2. Zannad F, Aliot E, Florentin J, Saulnier JP, Gilgenkrantz JM. Hemodynamic and electrophysiologic effects of rilmenidine for systemic hypertension. Am J Cardiol 1988; 61: 67D-71D.
3. Senechau P, Bousquet P, Dontenwill M. Imidazoline specific binding sites in the human kidney. Arch Pharmacol 1998; 358: R747.
4. Kline RL, Cechetto DF. Renal effects of rilmenidine in anesthetized rats: importance of renal nerves. J Pharmacol Exp Ther 1993; 266: 1556-62.
5. Kline RL, van der Mark J, Cechetto DF. Natriuretic effect of rilmenidine in anesthetized rats. Am J Cardiol 1994; 74: 20A-24A.
6. + transport and intracellular pH in renal proximal tubule cells. Bioch Bioph Acta 1990; 1024: 173-8.
7. 1 imidazoline receptor-selective compounds mediate natriuresis in the rat. J Cardiovasc Pharmacol 1995; 26 (Suppl 2): S63-S67.
8. 1 imidazoline receptor agonist, rilmenidine, in pentobarbital anaesthetized rats. Neurochem Int 1997; 30: 55-62.
9. Dstermann G, Brisgand B Schmitt J, Fillastre JP. Efficacy and acceptability of rilmenidine for mild-to-moderate systemic hypertension. Am J Cardiol 1988; 61: 76D-80D.
10. Fiorentini C, Guillet C, Guazzi M. Etude multicentrique en double aveugle comparant la rilmenidine 1 mg vers l'hydrochlorothiazide 25 mg chez 244 patients. Arch Mal Coeur Vaiss 1989; 82 (Suppl): 39-46.
11. Pelemans W, Corcoran C, van Dessel, Opsomer M. Efficacy and safety of rilmenidine in elderly patients: comparison with hydrochlorothiazide. Am J Cardiol 1994; 74: 51A-57A.
12. Dallocchlo M, Gosse P, Fillastre JP, et al. Rilmenidine, a new antihypertensive agent, in the first-line treatment of essential hypertension. A multicentre double-blind study versus atenolol. Arc Mal Coeur Vaiss 1991; 84 (Suppl): 42.
13. Sadowski Z, Szwed H, Kuch-Wocial A, et al. Regression of left ventricular hypertrophy in hypertensive patients after 1 year of treatment with rilmenidine: a double-blind, randomized, controlled (versus nifedipine) study. J Hypertens 1998; 16 (Suppl 3): S55-S62.
14. De Luca N, Izzo H, Fontana D, Trimarco B. Haemodynamic and metabolic effects of rilmenidine in hypertensive patients with metabolic syndrome X. A double-blind parallel study versus amlodipine. J Hypertens 2000; 18: 1519-22.
15. Scemama M, Fervier B, Beucler I, Dairou F, et le groupe des médicins Euraxi SA. Lipid profile and antihypertensive efficacy in dyslipidemic hypertensive patients: comparison of rilmenidine with captopril. J Cardiovasc Pharmacol 1995; 26 (Suppl 2): S34-S39.
16. Dupuy D, Beauduceau B, Mayandon H. Rilmenidine in the hypertensive type-2 diabetic: a controlled pilot study versus captopril. J Cardiovasc Risk 2000; 7: 57-61.
17. Fillastre JP, Letac B, Galinier F, Le Bihan G, Schwartz J. A multicenter double-blind comparative study of rilmenidine and clonidine in 333 hypertensive patients. Am J Cardiol 1988; 61: 81D-85D.
18. United Kingdom Working Party on Rilmenidine. Rilmenidine in mild-to-moderate essential hypertension. Curr Ther Res 1990; 47: 194-211.
19. Galley P, Manciet G, Hessel JL, Michel JR Antihypertensive efficacy and acceptability of rilmenidine in elderly hypertensive patients. J Am Cardiol 1988; 61: 86D-90D.
20. Beau B Mahieux F, Paraire M, Laurin S, Brisgand B, Vitou P. Efficacy and safety of rilmenidine for arterial hypertension. Am J Cardiol. 1988; 61: 95D-102D.
21. Luccioni R. Evaluation pharmacoépidémiologique de la chez 18235 hypertendus. Presse Med 1995; 34: 1857-64.
22. Velasco M, Soltero I, Sukerman M, et al. Double-blind, randomized study of the efficacy, tolerance and rebound effects of the antihypertensive drug rilmenidine: comparative evaluation with clonidine. Cirr Ther Res 1993; 54: 202-7.
23. Panfilov V, Morris A, Donnelly R, Reid JL, Comparative effects of rilmenidine and atenolol on tests of autonomic function and mental and dynamic exercise in patients with essential hypertension. J Cardiovasc Pharmacol 1995; 26 (Suppl 2): S44-S47.
24. Mpoy M, Vandeleene B, Ketelslegers JM, Lambert AE. Treatment of systemic hypertension in insulin-treated diabetes mellitus with rilmenidine. Am J Cardiol 1988; 61: 91D-94D.
25. Lubetzki J. Etude chez l'hypertendu diabetique non insulino-dépendant de l'activité antihypertensive et de l'acceptabilité de la rilménidine (S3341). Essai réalisé chez 16 patients traités pendant trois mois aux posologies journalières de 1 et 2 mg. Expert study 1996.
26. Trimarco B, Rosiello G, Sarno D, Argenziano L, Rubattu S, de Luca N, Volpe M. Rilmenidine in patients with left ventricular hypertrophy due to essential hypertension: beyond the reduction of left ventricular mass. J Cardiovasc Pharmacol 1995; 26 (Suppl 2): S29-S33.
27. Lengyel M, Borbas S, Zorandi A. Regression of left ventricular hypertrophy in mild-tomoderate hypertension in one year of treatment with rilmenidine. Eur Heart J 2000; 21 (Suppl): 101.